Trump Lays Waste to Democrats for Backing Nazi Candidate After Calling Him Hitler...
Middle School Teacher Fired After Pressuring Female Students to Kiss Each Other
Shocking Hockey News Out of Canada, While the American Press Is Still Bothered...
North Carolina Dem Senate Candidate Roy Cooper Is Peddling a Dangerous Lie
This California Congressman Is Reviving Calls for Secession
America Is About to Celebrate Her 250th Birthday. And Democrats Feel Nothing but...
An Iran Agreement Defined by Unanswered Questions
NRA, Gun Rights Groups Sue Michigan Over Firearm License, Registration Requirements
Trump and Iran Sign Preliminary Peace Agreement
FTC and States Sue Group That Pushed Deceptive Transgender Care Claims on Kids
Miami Woman Indicted in Scheme to Sell 6,000 Medicare Patients' Data
Brooklyn Retailer Indicted for Allegedly Stealing $640,000 in Ohio SNAP Benefits
Georgia Republicans Betray Voters, Reject Calls to Redistrict for 2028 Elections
Elected Officials Jump to Defend Giants Players From MLB Warning Over Written Bible...
Federal Reserve Announces Interest Rate Decision in First Post-Powell Meeting
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
West Virginia on the Right Track to Lower Drug Costs, But is it Enough?
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Related:

DRUGS HEALTH CARE

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement